Doximity slides in post-market trading after giving weak expectations for the current quarter
Medical software stock Doximity slid more than 8% in extended trading after issuing weak guidance for the current quarter.
The company said to expect between $106.5 million and $107.5 million in revenue and between $39 million and $40 million in adjusted EBITDA for the first fiscal quarter. Both of those estimates were below consensus expectations, with analysts polled by FactSet anticipating revenue at $11.8 million and adjusted EBITDA at $45.4 million.
That overshadowed results from the fourth fiscal quarter. The company reported 20 cents in earnings per share excluding items, above the 17 cents expected by analysts. Revenue also beat expectations at $111 million compared with a $110.1 million forecast. Adjusted EBITDA came in at $48.9 million, ahead of the $45.7 consensus estimate.
For the full fiscal year, the company said to expect between $500 million and $506 million in revenue, a range that contains the Wall Street estimate of $501.8 million. The company expects adjusted EBITDA for the year to come in between $216 million and $222 million, while analysts anticipate $215.7 million.
— Alex Harring
Stock futures are little changed
Stock futures were up modestly shortly after 6 p.m. ET.
Futures tied to the Dow, S&P 500 and Nasdaq 100 were all up around 0.1%.
— Alex Harring
